In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction
- Registration Number
- NCT05184530
- Brief Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitor among patients with acute myocardial infarction(AMI) based on real-world experience.
A total of 7556 AMI patients from the biobank database between January 2016 and December 2020 were screened for eligibility. After excluding those without revascularization or Statin based therapy, the remaining 5802 Statin users, 801 Statin plus Ezetimibe users and 170 Statin plus Evolocumab users (including 95 users without and 75 users with Ezetimibe), were selected for this study. Then, 1st and 3rd-month follow-up data were collected and analysed, including in-hospital mortality, readmission rate and lipid profiles
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 7556
- confirmed admission diagnosis of AMI and were defined based on the universal definition criteria by the American Cardiology College
- (1) severe noncardiac disease with an expected survival of less than 1 year and unwillingness to participate; (2) patients over the age of 80 years or living far away from the hospital's catchment area.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description PCSK9i Group Evolocumab 140 MG/ML AMI patients with Statin plus PCSK9i therapy. Triple Group Evolocumab 140 MG/ML AMI patients with Statin plus Ezetimibe plus PCSK9i therapy
- Primary Outcome Measures
Name Time Method Readmission rate 1 YEAR
- Secondary Outcome Measures
Name Time Method